Crinetics Pharmaceuticals Inc.
Clinical trials sponsored by Crinetics Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing therapies for endocrine diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame hormone disorder Cushing's syndrome Results expected Oct 2026 (estimated)
- New pill may help adults with rare adrenal disorder cut back on steroids Results expected May 2027 (estimated)
- New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers Results expected Aug 2027 (estimated)
- New pill aims to tame flushing and diarrhea in rare cancer syndrome Results expected Aug 2027 (estimated)
-
New pill shows promise for controlling acromegaly Long-Term
Disease control Stopped earlyThis study looks at the long-term safety and effectiveness of an oral medication called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. About 43 adults who finished a previous related study will take the drug and be monitored for …
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill could tame rare growth disorder without surgery
Disease control Stopped earlyThis study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a pill replace needles for acromegaly?
Disease control Stopped earlyThis study tests an oral drug called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. Participants had their disease under control with standard injections and were randomly assigned to receive either paltusotine or a placebo. The …
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC